Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
-
2541
-
2542
-
2543
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
2544
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
2545
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
2546
Baseline Characteristics of Study Participants.
Published 2025“…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …”
-
2547
Raw and processed data files.
Published 2025“…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …”
-
2548
-
2549
-
2550
-
2551
-
2552
Effects of busulfan treatment (6 mg/kg) on the body and testes weights of mice over three weeks.
Published 2025Subjects: -
2553
-
2554
-
2555
Effect of busulfan treatment on vimentin, a supporting cytoskeletal protein.
Published 2025Subjects: -
2556
-
2557
Effects of busulfan treatment on the ultrastructure of the blood-testis barrier (BTB).
Published 2025Subjects: -
2558
-
2559
-
2560
The relationship between residual shear strength and <i>JRC</i>, normal stress.
Published 2024Subjects: